NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Vitoria, Álava, Spain.
Clin Transl Oncol. 2012 Feb;14(2):83-93. doi: 10.1007/s12094-012-0766-6.
Conventional anticancer drugs display significant shortcomings which limit their use in cancer therapy. For this reason, important progress has been achieved in the field of nanotechnology to solve these problems and offer a promising and effective alternative for cancer treatment. Nanoparticle drug delivery systems exploit the abnormal characteristics of tumour tissues to selectively target their payloads to cancer cells, either by passive, active or triggered targeting. Additionally, nanoparticles can be easily tuned to improve their properties, thereby increasing the therapeutic index of the drug. Liposomes, polymeric nanoparticles, polymeric micelles and polymer- or lipid-drug conjugate nanoparticles incorporating cytotoxic therapeutics have been developed; some of them are already on the market and others are under clinical and preclinical research. However, there is still much research to be done to be able to defeat the limitations of traditional anticancer therapy. This review focuses on the potential of nanoparticle delivery systems in cancer treatment and the current advances achieved.
传统抗癌药物存在明显的缺陷，限制了其在癌症治疗中的应用。因此，纳米技术领域取得了重要进展，以解决这些问题，并为癌症治疗提供有前途和有效的替代方法。纳米颗粒药物递送系统利用肿瘤组织的异常特征，通过被动、主动或触发靶向作用，选择性地将其有效载荷递送到癌细胞。此外，还可以对纳米颗粒进行容易的调整，以改善其性质，从而提高药物的治疗指数。已经开发了包含细胞毒性治疗剂的脂质体、聚合物纳米颗粒、聚合物胶束和聚合物/脂质药物偶联纳米颗粒；其中一些已上市，还有一些正在进行临床前和临床研究。然而，要克服传统抗癌疗法的局限性，仍有许多研究工作要做。这篇综述重点介绍了纳米颗粒递送系统在癌症治疗中的潜力和目前取得的进展。
